Self-reported pharmacogenetic medication use in the Our Future Health cohort
Abstract
ABSTRACT:
Aim: To describe self-reported use of medications with pharmacogenetic guidance in the Our Future Health (OFH) cohort.
Methods: We focused on four key pharmacogenes— CYP2C19, CYP2C9, CYP2D6 , and SLCO1B1 —and associated medications supported by high levels of evidence for clinical actionability according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). We summarized self-reported pharmacogenetic medication use, assessed concurrent use, and stratified the findings by age, sex, and ethnicity.
Results: Self-reported medication use was analysed in 1.78 million OFH cohort participants included in the June 2025 data release. The cohort was 57.3% female, ranged in age from 18 to 95 years (mean 53.1 years), and 90.2% self-identified as being of “White” ethnicity. Participants reported use of 18 medication groups that were explicitly mentioned in the baseline questionnaire. Due to the structure of the baseline questionnaire, it was only possible to identify exposure to medication groups rather than mention of specific individual medications. Medications and medication groups with pharmacogenetic guidance included anti-depressants (selective serotonin reuptake inhibitors and tricyclics), statins, proton pump inhibitors, ibuprofen, opioids, clopidogrel and warfarin. A total of 25.2% (N=449,641) of the cohort reported using at least one of these medication groups, and were older, more likely to be female, and reported having more medical conditions than…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 449,641 participants or records.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.